E-mail

E-mail a Wiley Online Library Link

U. Mrowietz, K. Kragballe, K. Reich, C.E.M. Griffiths, Y. Gu, Y. Wang and S.J. Rozzo An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals British Journal of Dermatology 168

Version of Record online: 13 DEC 2012 | DOI: 10.1111/j.1365-2133.2012.11214.x

What’s already known about this topic?

  •  A variety of medical organizations and national agencies have published guidelines and recommendations for the treatment of moderate to severe psoriasis.
  •  The European Consensus Programme (ECP) recently developed and published the first pan-European consensus statement on treatment goals for moderate to severe psoriasis.
  •  The results of the ECP included an emphasis on evaluation of both clinical disease status and patient quality of life following treatment, as well as recommendations for continuation or modification of therapy based on whether the treatment goals had been achieved.

What does this study add?

  •  Using the ECP treatment goals, we assessed the treatment efficacy of adalimumab in patients participating in Phase III clinical trials who met the ECP criteria for moderate to severe psoriasis.
  •  Over 70% of patients in these trials attained treatment goals; of these, > 93% of patients had a > 75% improvement in their Psoriasis Area and Severity Index score.
  •  Results support the use of the ECP treatment goals that were consistent for all three trials and indicate that adalimumab induced highly efficacious, generally consistent responses and would inform continued, unmodified therapy in > 70% of patients with psoriasis.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH